Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04670679
Title FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Acronym FLAGSHP-1
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Erasca, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35294 United States Details
University of California, San Diego San Diego California 92093 United States Details
Sarah Cannon Research Institute (Florida Cancer Specialists) Sarasota Florida 34232 United States Details
Massachusetts General Hospital Boston Massachusetts 02215 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Comprehensive Cancer Centers of Nevada Henderson Nevada 89014 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of North Carolina Chapel Hill North Carolina 27599 United States Details
University of Cincinnati Cincinnati Ohio 45267 United States Details
University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
Sarah Cannon Research Institute (Tennessee Oncology) Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Dallas Texas 75251 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Peter MacCallum Cancer Centre Melbourne Victoria Australia Details
Linear Clinical Research Perth Western Australia Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field